anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: In France, since 2017 the law has allowed people to change the gender marker on their civil status documents without having undergone medical treatment and sterilization surgery. However, no legislative framework has been provided to ensure their right to family, leaving those who wish to become parents in a space of social, political, and legal uncertainty that is inconsistent with international and human rights. In parallel, France has developed an arsenal of health strategies that constrain actors working in the field.
PURPOSE OF THE RESEARCH: This study examines the possibilities available to public health actors for promoting reproductive health in the absence of legislation and in the context of political and legislative adversity. To this end, it relies on a participatory, critical, and lexicometric analysis of national strategies for sexual and reproductive health and parenthood support.
RESULTS: Governance strategies make no mention of parentality among transgender people. Sexual and reproductive health policies focus on tackling sexually transmitted infections, on health pathways, and on violence and discrimination. The analysis also highlights a lack of awareness on this topic.
CONCLUSIONS: Shortcomings in the legislative framework and public health strategies raise ethical questions about the promotion of reproductive health and the potentially non-inclusive approach of actors in the field. These issues force communities to carry out actions outside the scope of ordinary regulations, and they highlight the political positioning of the public-health field in France.
Healthy participants that have never smoked. Definition of never-smoker: Lifetime consumption of \<100 cigarettes. No cigarettes the past 2 years.
<P>PROBLEM TO BE SOLVED: To allow a user to safely disclose a personal information database to persons other than himself or to organizations.  <P>SOLUTION: A personal terminal 50 transmits to a relay server 40 a request to disclose the user's electronic chart information to a hospital D. The relay server 40 sets an authority to disclose the user's chart information to the first hospital D. The personal terminal 50 sends a notice to the first hospital's terminal 60 indicating that the authority has been set in the relay server 40. The first hospital's terminal 60 transmits to the relay server 40 the request to disclose the user's chart information. The relay server 40 transmits to a second hospital data server 10 the request to disclose the chart information. If the request to disclose the electronic chart information that has been transmitted from the relay server 40 is legitimate, the second hospital data server 10 transmits the electronic chart information to the relay server 40. Upon receiving the electronic chart information, the relay server 40 transmits the electronic chart information to the first hospital's terminal 60.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
BACKGROUND: The treatment of persistent fatigue after COVID-19 infection is complex. On the one hand, it involves maintaining a sufficient level of physical and mental activity to counteract possible degenerative processes of the body and nervous system. On the other hand, physical and mental activities can also lead to worsening of symptoms. Therefore, the challenge in treating Post-COVID fatigue is to stimulate the body and central nervous system in a way that stimulates growth and improvement, but does not overtax individual physical and mental limits. Special training programs try to take these characteristics into account, but often reach their limits. A promising approach is offered by new fitness technologies based on immersive virtual realities that stimulate both body and brain while minimizing physical and psychological stress. The aim of this study is to investigate the efficacy of supervised immersive Virtual Reality (VR)-based activity training compared to conventional activity training for patients with Post-COVID-associated fatigue.
METHODS: In a single centre, individually randomised, prospective, double-blind two-arm exploratory superiority trial with parallel group design, N = 100 patients with persistent fatigue after COVID-19 infection will be recruited. The intervention includes a supervised immersive neuromuscular training (12 sessions of 30 min over 6 weeks) based on a novel VR-exercise device. We will systematically compare the effects of this intervention on Post-COVID-associated fatigue with a supervised conventional activation program of comparable scope without an immersive environment. The primary outcome is the difference between groups in absolute change in the mean fatigue symptom severity measured on the Fatigue Severity Scale (FSS) from baseline to posttreatment assessment. Posttreatment assessment in both groups will be conducted by blinded outcome assessors. At three and six months afterwards, patients are sent self-report questionnaires for follow up. The main analysis will be based on the intention-to-treat principle.
DISCUSSION: To the best of our knowledge, this is the first exploratory study on a supervised immersive neuromuscular training for the treatment of persistent fatigue after COVID-19 infection.
TRIAL REGISTRATION: German register for clinical studies (ID: DRKS00032059) Prospectively registered on June 16th 2023. URL of trial registration.
Convulsive status epilepticus (CSE) is a common critical neurological condition that can lead to irreversible hippocampal neuron damage and cognitive dysfunction. Multiple studies have demonstrated the critical roles that long non-coding RNA Mir155hg plays in a variety of diseases. However, less is known about the function and mechanism of Mir155hg in CSE. Here we investigate and elucidate the mechanism underlying the contribution of Mir155hg to CSE-induced hippocampal neuron injury. By applying high-throughput sequencing, we examined the expression of differentially expressed genes in normal and CSE rats. Subsequent RT-qPCR enabled us to measure the level of Mir155hg in rat hippocampal tissue. Targeted knockdown of Mir155hg was achieved by the AAV9 virus. Additionally, we utilized HE and Tunel staining to evaluate neuronal injury. Immunofluorescence (IF), Golgi staining, and brain path clamping were also used to detect the synaptic plasticity of hippocampal neurons. Finally, through IF staining and Sholl analysis, we assessed the degree of microglial phagocytic function. It was found that the expression of Mir155hg was elevated in CSE rats. HE and Tunel staining results showed that Mir155hg knockdown suppressed the hippocampal neuron loss and apoptosis followed CSE. IF, Golgi staining and brain path clamp data found that Mir155hg knockdown enhanced neuronal synaptic plasticity. The results from IF staining and Sholl analysis showed that Mir155hg knockdown enhanced microglial phagocytosis. Our findings suggest that Mir155hg promotes CSE-induced hippocampal neuron injury by inhibiting microglial phagocytosis.
Novel quinolone derivatives are disclosed. Also disclosed are synthesis and use thereof for treating neurodegenerative diseases. In an aspect, the invention relates to a composition comprising a therapeutically effective amount of the compound as aforementioned, or a pharmaceutically acceptable salt, a solvate or hydrate, a prodrug, or a metabolite thereof and a pharmaceutically acceptable diluent or carrier. Further in another aspect, the invention relates to a composition comprising a compound as aforementioned, or a pharmaceutically acceptable salt, a solvate or hydrate, a prodrug, or a metabolite thereof, and a pharmaceutically acceptable diluent or carrier tor use in treating a neurodegenerative disease. Yet in another aspect, the invention relates to a use of a compound as aforementioned in the manufacture of a medicament for treating a neurodegenerative disease. In one embodiment, the medicament is for treating.Alzheimer's disease.
Participants in the Mindful Hand Hygiene Intervention will complete the same surveys as participants in the Control Arm at baseline, post-intervention, and 6-months post-intervention. Data will also be collected on baseline hand-hygiene rates during the habituation period, intervention period, and 3-12 months post-intervention. In addition, intervention participants will be asked to complete 3 mindfulness online educational modules and attend group-facilitated discussions on mindfulness. They will be offered the option of using a mobile application program "Mindfulness Coach" to enhance their mindfulness practices. A key message of the intervention is using hand hygiene as a prompt to practice mindfulness.
Currently, lifestyle habits of workers does not only represents a personal concern, but also a concern of the company. Currently there are very few studies that efficiently integrate classical interventions (screening) and online tools in order to obtain sustainable lifestyle changes in workers. The current project aims to evaluate efficacy of a combined approach versus more traditional approaches. Health Data collected by CAPSANA in the workplace between 2012 and 2014 showed that, out of 4231 workers, 69% should aim at a more active lifestyle and 74% at a better nutritional profile. In addition, 53% of the sampled population were overweight.

In this context, the current project aims to motivate and follow individuals towards a healthier lifestyle. To do so, the Activate Your Health will be implemented and tested using various options (limited to more complete) in several companies. It is planned to compare to a control group receiving no intervention to the other groups containing little to complete set of interventions. The content of the interventions involves health assessment, electronic tools (SOScuisine and social media platform), health screening, activity monitor tool and closing events. The companies had to pick which option they would like to provide their employees. It is anticipated that the complete option will yield better results for the activity profile and other lifestyle habits. For example, changes in eating habits toward better habits are expected.
Optic Neuropathy and Optic Neuritis   
Cases of optic neuropathy and optic neuritis, usually resulting in visual impairment and sometimes permanent blindness, have been reported in patients treated with amiodarone and may occur at any time during therapy. If symptoms of visual impairment appear, such as changes in visual acuity and decreases in peripheral vision, consider discontinuing amiodarone hydrochloride and promptly refer for ophthalmic examination. Regular ophthalmic examination, including funduscopy and slit-lamp examination, is recommended during administration of amiodarone hydrochloride [see Adverse Reactions (6.1)]. 

Corneal Microdeposits   
Corneal microdeposits appear in the majority of adults treated with amiodarone hydrochloride. They are usually discernible only by slit-lamp examination, but give rise to symptoms such as visual halos or blurred vision in as many as 10% of patients. Corneal microdeposits are reversible upon reduction of dose or termination of treatment. Asymptomatic microdeposits alone are not a reason to reduce dose or discontinue treatment [see Adverse Reactions (6.1)].
FIELD: medicine. SUBSTANCE: preparation has at least one substrate with properties of original medication preparation like Tuberculinum nosodeme and homeopathic preparation of Kreozotum retained. Sugar or wax, or water, or glycerol solution, or alcohol solution is selected as the substrate. Additional original medication preparations like Pneumococcine nosodeme and homeopathic preparation of Potassium bichronicum, or Mononucleosis nosodeme and homeopathic preparation of Rus toxodendron, or Streptococcus nosodeme and homeopathic preparation of Hamomellis are optionally introduceable into the preparation. EFFECT: enhanced effectiveness of treatment; prevented disease recurrence. 5 cl
PROBLEM TO BE SOLVED: To obtain the subject composition useful as a dental adhesive capable of stably maintaining a high adhesive strength for a long period without requiring a pretreatment such as an etching treatment by including a polymerizable compound having an acidic group, a water-soluble film-forming agent, water and a curing agent. SOLUTION: This composition is obtained by including (A) a polymerizable compound having an acidic group, (B) a water-soluble film-forming agent, (C) water and (D) a curing agent. A calcium salt of the polymerizable compound of the component A is insoluble in water and the compound A is, e.g. 10- methacryloyloxydecyl phosphate. The component B is a polymerizable compound miscible with a physiological saline and is, e.g. 2-hydroxyethyl methacrylate. The component D is a polymerization accelerator [e.g. N,N-bis(2-hydroxyethyl)-p- toluidine], (a photo- or a thermal) polymerization initiator (e.g. camphor-quinone or benzoyl peroxide), or the like.
PURPOSE: Seroma formation is the most common cause of morbidity associated with laparoscopic inguinal hernia repair. This study aimed to examine the relationship between the thickness of subcutaneous fat (TSF) and the risk of postoperative seroma.
METHODS: We reviewed data from a prospective cohort of 229 male patients who underwent laparoscopic total extra-peritoneal (TEP) hernioplasty for indirect inguinal hernia between August 2018 and July 2021. The TSF was assessed using preoperative ultrasound images. The risk factors for postoperative seroma were determined using univariate and multivariate logistic regression models.
RESULTS: Postoperative seromas occurred in 26 patients (11.4%). The factors associated with postoperative seroma included longer hernia duration, larger hernia defects, extension into the scrotum, and greater TSF (P < 0.05). In multivariate analysis, a greater TSF was independently associated with a greater risk of postoperative seroma (per 1 mm: odd ratio [OR] 1.105, 95% confidence interval [CI] 1.048-1.165, P < 0.001; TSF ≥ 26.0 mm: OR 7.033, 95% CI 2.485-19.901, P < 0.001). Similar results were obtained in the subgroup analysis. The area under the curve of TSF for predicting seroma formation was 0.703 (95% CI 0.601-0.806).
CONCLUSION: Ultrasound-derived TSF may be a promising prognostic factor for postoperative seroma in patients undergoing laparoscopic TEP repair. Further validation is required and then this parameter can be used to improve decision-making process.
C A N A D A            S P E C I F I C A T I O N     TO ALL WHOM IT MAY CONCERN:     Be it known that I, NEIL BONNETTE GRAHAM, a dual U.K. and Canadian Citizen of 6, Kilmardinny Grove, Bearsden, Glasgow, Scotland G61 3NY have invented certain new and useful improvement in HYDROGEL-CONTAINING ENVELOPES and the following disclosure contains a full description of the invention and of the best mode known to the inventor for taking advantage of same.             ABSTRACT OF DISCLOSURE    An envelope having flexible water-permeable or porous walls contains a quantity of particulate water-insoluble hydrogel.  The quantity of hydrogel in the envelope is such that, when the hydrogel is fully swollen at 20°C, its volume is at least 66%, preferably at least 100%, of the maximum non-stretched internal volume of the envelope.  Thus, the envelope according to the invention is limp and floppy under dry conditions but in a wet environment the hydrogel absorbs water and sells accordingly causing the envelope to swell and take on a more rigid configuration.  The envelope is particularly useful for the administration of sustained release pharmaceutically or veterinarily  active ingredients. Thus the limp dry envelope may for example be rolled up for introduction through the throat but will swell up and therefore be retained in the stomach for sustained release of the active ingredient therein.
Participants with DS or LGS will receive soticlestat, mini-tablets, at the starting dose of 100 mg to 300 mg, administered orally with or without food (oral or enteral feeds), twice daily (BID) based on body weight up to 4 weeks in Titration Period. Participants will continue to receive the dose that they are on at the end of the titration period, for first 12 weeks in the Maintenance Period. The dose can be adjusted in the maintenance period as per the body weight after the initial 12 weeks. Dose will be tapered down if participants decide to discontinue the treatment. Total duration of the treatment will be up to approximately 52 weeks.
PURPOSE: To provide substantially the same biological activity as hirudin by combining a functional group of a supporting material directly with hirudin or proteins of hirudin derivatives utilizing anhydrous or aqueous combining reactions. CONSTITUTION: To the active functional groups of a supporting material such as hydroxyl group, carboxyl group or amino group, hirudin or proteins of hirudin derivatives is combined by functional groups of amino acid residues. Here, materials and protein include natural products, genetic derivatives and synthetic substances. Methods of combining depend upon factors such as useful functional groups of the support materials, the combining positions of proteins, biological activity of materials obtained, and selectivity and efficiency of combining reactions. There are two methods; one performed under an anhydrous or aqueous condition and the other using dual active protein cross-linking reagents. During this combining process, the active functional group of the amino acid residue is protected.
PROBLEM TO BE SOLVED: To provide an aerosol type mousse for dyeing the hair and making it beautiful. SOLUTION: An effective component in henna is deteriorated in the presence of water with time when the powder or extracts of the henna plant which has been used as a hair dyeing agent in Europe and America from oil times are processed to mousse formulation. The hair dye for Japanese is necessarily adjusted in the color because the hair color dyed with henna is red to yellow. The deterioration of lawsone, effective component of henna is resolved by setting the liquid in a reduced ambience. Therefor the filtrate of the product should have more than 1 N conversion (30 μl/filtrate 1 ml) of the consumed amount under the quantitative analysis by KMnO4 standard solution, and less than 30 ml/filtrate 1 ml because solidification takes mush time at hair dyeing treatment when too much filtrate is used. The color is adjusted together with basic oxidation dye.  Henna plant powder pulverized in less than 0.25 mm or henna extracts, an antioxidant, an whipping agent and the like are combined to form a stock solution and filled with a liquid gas to form aerosol mousse.
FIELD: medical cosmetology. SUBSTANCE: curative-and-cosmetic agent contains an effective ingredient and base-forming component. Used as an effective ingredient is the composition including substance possessing ability to arrest bleeding, stimulator hemoxygenas, medicine for improving peripheric blood supply, and solvent. All components are take in determined quantitative ratio. Claimed agent reduces time of ecchymoses resorption in 2-3 times. EFFECT: new curative-and-cosmetic agent without side effects and irritation. 11 cl, 1 tbl, 2 ex
Compounds are disclosed that inhibit enzymes of the uracil base excision repair (UBER) pathway. Inhibitors of uracil DNA glycosylase, pUTPase and AP endonuclease I are disclosed. The compounds can comprise a uracil substrate fragment and a second binding element joined covalently together by a linker molecule. The compounds are also disclosed comprising a uracil substrate fragment, a second binding element, and a third binding element, which a joined together covalently by a linker molecule. Also disclosed are methods for treating diseases and disorders in a subject in need of treatment where the disorder and/or diseases include cancer and bacterial, viral, and parasitic infections and where the method includes the step of administering the disclosed inhibitors. The administered inhibitors inhibition the enzymes of the UBER pathway, thereby treating the diseases and disorders disclosed herein.
ACCUPRIL has been evaluated for safety in 4960 subjects and patients. Of these, 3203 patients, including 655 elderly patients, participated in controlled clinical trials. ACCUPRIL has been evaluated for long-term safety in over 1400 patients treated for 1 year or more.

Adverse experiences were usually mild and transient.

In placebo-controlled trials, discontinuation of therapy because of adverse events was required in 4.7% of patients with hypertension.

Adverse experiences probably or possibly related to therapy or of unknown relationship to therapy occurring in 1% or more of the 1563 patients in placebo-controlled hypertension trials who were treated with ACCUPRIL are shown below.
The physical, psychological and social consequences of alcohol abuse remain a critical health problem. Every year in Australia, excessive consumption is responsible for 3,000 - 6,000 deaths and costs the community $6 billion. Approximately 15% of Australians abuse alcohol and 5% of men and 3% of women are alcohol dependent (addicted to alcohol). Better treatment for alcohol dependence is urgently needed. Treatment for alcohol dependence remains unsatisfactory. Most treatments lead to abstinence in only 1 out of 3 cases, and approximately 50% of these will relapse within 3 months of completing treatment. Two drugs (naltrexone and acamprosate) appear to interfere with the effects of alcohol on the brain that promote addiction. There is evidence that both drugs are beneficial in the treatment of alcohol dependence and both are now available in Australia. At present, no data have been reported comparing the effectiveness of these two drugs. The proposed project will compare naltrexone and acamprosate in a large, carefully performed, study. The study will help determine which subjects are likely to benefit from one or the other of these agents.
PURPOSE:To obtain a remedy for steatorrhea, containing active type vitamin D as an active ingredient, capable of exhibiting remarkable treating effects on steatorrhea in malabsorption syndromes of fats and useful for improving fat content in feces. CONSTITUTION:A remedy containing active type vitamin D (e.g. 1alpha- hydroxyvitamin D, 1alpha,24-dihyroxyvitamin D, 1alpha,25-dihydroxyvitamin D, 1alpha,24,25- dihydroxyvitamin D, 24,24-F2-1alpha,25-dihydroxyvitamin D or 26,26,26,27,27,27- F6-1alpha,25-dihydroxyvitamin D) as an active ingredient. The active type vitamin D includes active type vitamins D2 and D3 and derivatives thereof. Among them, the 1alpha-hydroxyvitamin D3 is especially preferred. The above-mentioned ingredient is normally formulated so as to satisfy conditions of about 0.01-10mug/ day/human does administered in 1-3 divided portions a day.
An agent for hair treatment comprising two components, of which the first is anionic surfactant-free, contains the following :(A) at least one chitosan (derivative) at least partially neutralised with an (in)organic acid, present in the second component ; and (B) at least one anionic surfactant present in the second component. A hair treatment method in which the two components are mixed together and then applied onto the hair, or the two components are applied onto the hair separately in succession, is also claimed. Preferably the first component contains 0.01-20 wt.% (A), 60-99 wt.% water and has a pH of 2-5. The second component contains 0.01-70 wt.% (B), 15-90 wt.% water and has a pH of 3-9. (B) is chosen from alkali(ne earth) metal salts of 10-18C alkyl sulph(on)ates, 10-18C alkyl benzene sulphonates, 10-18C xylene sulphonates, ethoxylated 10-18C alkyl ether sulphates containing 1-10 ethylene oxide (EO) units, ethoxylated sulphosuccinic acid hemiesters or alkyl ether carboxylates. (A) has a molecular weight of 200000-5000000 g/mole and a degree of deacetylisation of 10-99 %. The acid used to neutralise (A) is hydrochloric acid, formic acid, acetic acid, lactic acid, glycolic acid, malonic acid, benzoic acid, adipic acid, citric acid, benzene disulphonic acid, chlorosulphonic acid or pyrrolidone carboxylic acid. A third component (C) is also present, comprising at least one nonionic or cationic thickener, in an amount of 0.01-10 wt.%.